Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 12070.155 | 0.9636 | 0.9377 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 12070.155 | 0.9194 | 0.8618 | 1.1729 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 12112.155 | 1.0145 | 1.0161 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 12112.155 | 1.0217 | 1.0241 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 12112.155 | 1.0071 | 1.0079 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 12112.155 | 1.0100 | 1.0111 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 12112.155 | 0.9061 | 0.8932 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 12112.155 | 0.7580 | 0.7141 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 12112.155 | 0.6738 | 0.6053 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 12112.155 | 0.7463 | 0.6994 | 1.7965 | |
| HCC1143 | TNBC | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 12112.155 | 0.6478 | 0.5706 | 1.7965 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 10753.146 | 0.9579 | 0.9416 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 10753.146 | 0.9204 | 0.8888 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 10753.146 | 0.9700 | 0.9584 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 10753.146 | 0.9353 | 0.9098 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 10753.146 | 0.9060 | 0.8684 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 10753.146 | 0.8794 | 0.8305 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 10753.146 | 0.8727 | 0.8208 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 10753.146 | 0.8396 | 0.7729 | 1.4503 | |
| HCC1187 | TNBC | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 10753.146 | 0.7904 | 0.7006 | 1.4503 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.000128 | uM | 12000.155 | 0.9459 | 0.8747 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.00064 | uM | 12000.155 | 0.8739 | 0.7096 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.0032 | uM | 12000.155 | 0.9236 | 0.8233 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.016 | uM | 12000.155 | 0.8925 | 0.7520 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.08 | uM | 12000.155 | 0.8825 | 0.7292 | 0.8592 |